
(AGENPARL) – Wed 24 September 2025 6.21 PM CEST / 24-Sep-2025 / Hansa Biopharma AB (STO:HNSA)
· At 12 months, mean eGFR was 51.5 mL/min/1.73m[2] in the imlifidase arm versus
19.3 mL/min/1.73m[2] in the control arm with a statistically significant and
clinically meaningful difference of 32.2 mL/min/1.73m[2] ( p